Veytics Intelligence
2026-10-12 · NASDAQ

Johnson & Johnson vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?

Key PointsJohnson & Johnson's fiscal 2025 sales rose about 6% to $94.2 billion, and its net income includes a roughly $7 billion reversal of its talc reserve.

Lire le briefing complet de Veytics

Nous affichons publiquement l'idee principale. Creez un compte gratuit pour lire l'article complet, l'enregistrer, le commenter et le relier au contexte marches et OSINT.